Advertisement

Journal of Neuro-Oncology

, Volume 53, Issue 3, pp 259–265 | Cite as

A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases

  • Lauren E. Abrey
  • Jon D. Olson
  • Jeffrey J. Raizer
  • Michelle Mack
  • Ann Rodavitch
  • Dina Y. Boutros
  • Mark G. Malkin
Article

Abstract

Background: Treatment options for patients with recurrent brain metastases are extremely limited. This study was designed to determine the safety and efficacy of temozolomide in the treatment of recurrent or progressive brain metastases.

Patients and methods: Forty-one patients (11 men, 30 women) with a median KPS of 80 were treated with temozolomide 150 mg/m2/day (200 mg/m2/day if no prior chemotherapy) for 5 days; treatment cycles were repeated every 28 days. Primary tumor types included 22 non-small cell lung, 10 breast, three melanoma, two small cell lung, two rectal, one ovarian and one endometrial cancer.

Results: There were five episodes of grade 3 thrombocytopenia and one grade 4 leukopenia. Significant non-hematologic toxicity possibly related to temozolomide included pneumonitis [2], constipation [1], and elevated liver enzymes [2]. Thirty-four patients were assessed for radiographic response; two had a partial response, 15 stable disease and 17 progressed. Both objective responses were seen in patients with non-small cell lung cancer. Overall median survival was 6.6 months.

Conclusions: Single agent temozolomide achieved disease control (PR or SD) in 41% of patients with recurrent brain metastases from a variety of primary malignancies with minimal toxicity. Therefore, temozolomide may be a reasonable treatment option for some patients with recurrent brain metastases.

brain metastases chemotherapy lung cancer temozolomide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Raymond E, Izbicka E, Soda H, Gerson SL, Dugan M, VonHoff DD: Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 3: 1769–1774, 1997Google Scholar
  2. 2.
    Stupp R, Ostermann S, Leyvraz S, Csaijka C, Buclin T, Decosterd LA: Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Amer Soc Clin Oncol 20: 59a, 2001Google Scholar
  3. 3.
    Fleming TR: One sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143–151, 1982Google Scholar
  4. 4.
    Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958Google Scholar
  5. 5.
    Christodoulou C, Bafaloukos D, Kosmidis P, Papakostas P, Skarlos DV: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12: 249–254, 2001Google Scholar
  6. 6.
    Bindal RK, Sawaya R, Leavens ME, Hess KR, Taylor SH: Reoperation for recurrent metastatic brain tumors. J Neurosurg 83: 600–604, 1995Google Scholar
  7. 7.
    Arbit E, Wronski M, Burt M, Galicich JH: The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with nonsmall cell lung cancer. Cancer 76: 765–773, 1995Google Scholar
  8. 8.
    Davey P, O'Brien PF, Schwartz ML, Cooper PW: A phase I/II study of salvage radiosurgery in the treatment of recurrent brain metastases. Br J Neurosurg 8: 717–723, 1994Google Scholar
  9. 9.
    Alexander E, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS: Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87: 34–40, 1995Google Scholar
  10. 10.
    Coia LR: The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 23: 222–238, 1992Google Scholar
  11. 11.
    Abdel-Wahab MM, Wolfson AH, Raub W, Landy H, Feun L, Sridhar K, Brandon AH, Mahmood S, Markoe AM: The role of hyperfractionated re-irradiation in metastatic brain disease: a single institutional trial. Am J Clin Oncol 20: 158–160, 1997Google Scholar
  12. 12.
    Lesser GJ: Chemotherapy of cerebral metastases from solid tumors. Neurosurg Clin N Am 7: 527–535, 1996Google Scholar
  13. 13.
    Kaba SE, Kyritsis AP, Hess K, Yung WKA, Mercier R, Dakhil S Jaeckle KA, Levin VA: TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15: 1063–1070, 1997Google Scholar
  14. 14.
    Alexander EI, Loeffler JS: Recurrent brain metastases. Neurosurg Clin N Am 7: 517–526, 1996Google Scholar
  15. 15.
    Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, Carlini P, Boni C, Di Sarra S: Front-line chemotherapy with Cisplatin and Etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma. Cancer 85: 1599–1605, 1999Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Lauren E. Abrey
    • 1
  • Jon D. Olson
    • 1
  • Jeffrey J. Raizer
    • 1
  • Michelle Mack
    • 1
  • Ann Rodavitch
    • 1
  • Dina Y. Boutros
    • 1
  • Mark G. Malkin
    • 1
  1. 1.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations